TGFB1 and diabetic kidney disease: TGF-β inhibitors have been extensively studied in both preclinical and clinical settings for their potential to alleviate renal fibrosis, improving renal function, and decreasing proteinuria in various CKD models, including UUO (Moon et al. 2006) and DKD (Benigni et al. 2006).